UBS Group’s AstraZeneca AZN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $31.4M | Buy |
+159,151
| New | +$30.7M | ﹤0.01% | 2116 |
|
|
2025
Q2 | – | Sell |
-7,500
| Closed | -$1.1M | – | 10240 |
|
|
2025
Q1 | $1.1M | Buy |
+7,500
| New | +$1.09M | ﹤0.01% | 5201 |
|
|
2024
Q4 | – | Sell |
-5,000
| Closed | -$779K | – | 9915 |
|
|
2024
Q3 | $779K | Sell |
5,000
-2,500
| -33% | -$404K | ﹤0.01% | 4873 |
|
|
2024
Q2 | $1.17M | Buy |
7,500
+800
| +12% | +$120K | ﹤0.01% | 4269 |
|
|
2024
Q1 | $908K | Sell |
6,700
-5,250
| -44% | -$695K | ﹤0.01% | 4679 |
|
|
2023
Q4 | $1.61M | Sell |
11,950
-13,100
| -52% | -$1.7M | ﹤0.01% | 4039 |
|
|
2023
Q3 | $3.39M | Buy |
25,050
+15,750
| +169% | +$2.15M | ﹤0.01% | 2940 |
|
|
2023
Q2 | $1.33M | Buy |
9,300
+2,350
| +34% | +$346K | ﹤0.01% | 3961 |
|
|
2023
Q1 | $965K | Buy |
+6,950
| New | +$935K | ﹤0.01% | 4132 |
|
|
2022
Q2 | – | Sell |
-64,800
| Closed | -$8.6M | – | 10303 |
|
|
2022
Q1 | $8.6M | Sell |
64,800
-62,550
| -49% | -$7.5M | ﹤0.01% | 2058 |
|
|
2021
Q4 | $14.8M | Buy |
+127,350
| New | +$15M | ﹤0.01% | 1798 |
|
|
2021
Q1 | – | Sell |
-20,000
| Closed | -$2M | – | 8980 |
|
|
2020
Q4 | $2M | Buy |
+20,000
| New | +$2.12M | ﹤0.01% | 3410 |
|
|
2020
Q1 | – | Sell |
-12,900
| Closed | -$1.29M | – | 7947 |
|
|
2019
Q4 | $1.29M | Buy |
+12,900
| New | +$1.21M | ﹤0.01% | 3973 |
|
|
2019
Q3 | – | Sell |
-71,600
| Closed | -$5.91M | – | 7986 |
|
|
2019
Q2 | $5.91M | Buy |
71,600
+51,900
| +263% | +$4.07M | ﹤0.01% | 2188 |
|
|
2019
Q1 | $1.59M | Buy |
+19,700
| New | +$1.55M | ﹤0.01% | 3190 |
|
|
2018
Q3 | – | Sell |
-25,000
| Closed | -$1.76M | – | 7963 |
|
|
2018
Q2 | $1.76M | Buy |
25,000
+12,500
| +100% | +$899K | ﹤0.01% | 3284 |
|
|
2018
Q1 | $874K | Buy |
+12,500
| New | +$866K | ﹤0.01% | 3826 |
|
|
2017
Q4 | – | Sell |
-50
| Closed | -$3K | – | 7831 |
|
|
2017
Q3 | $3K | Sell |
50
-337,450
| -100% | -$21.3M | ﹤0.01% | 7384 |
|
|
2017
Q2 | $23M | Buy |
+337,500
| New | +$22M | 0.01% | 970 |
|
|
2016
Q1 | – | Sell |
-3,100
| Closed | -$210K | – | 7628 |
|
|
2015
Q4 | $210K | Sell |
3,100
-300
| -9% | -$19.7K | ﹤0.01% | 4627 |
|
|
2015
Q3 | $216K | Sell |
3,400
-29,900
| -90% | -$1.97M | ﹤0.01% | 4569 |
|
|
2015
Q2 | $2.12M | Sell |
33,300
-50,700
| -60% | -$3.47M | ﹤0.01% | 2912 |
|
|
2015
Q1 | $5.75M | Sell |
84,000
-220,300
| -72% | -$15.3M | ﹤0.01% | 1958 |
|
|
2014
Q4 | $21.4M | Buy |
+304,300
| New | +$21.8M | 0.02% | 943 |
|
Other funds holding AZN
IA
VCM
VAM
UBS Group's AZN Position: Q1 2026 in Review
UBS Group increased its AstraZeneca (AZN) stake by 316% in Q1 2026, buying an estimated $876M and bringing the position to 5,981,411 shares worth $1.18B. The position accounts for 0.18% of the portfolio, ranked #107.
UBS Group first reported a position in AZN in Q4 2014 and has held it in 46 quarters since. 1,377 funds tracked by Wall St. Rank hold AZN as of Q1 2026.
- UBS Group held 5,981,411 shares of AstraZeneca worth $1.18B as of Q1 2026.
- UBS Group bought 4,542,013 AstraZeneca shares in Q1 2026, an estimated $876M.
- AstraZeneca made up 0.18% of UBS Group's portfolio in Q1 2026, its #107 holding.
- UBS Group first reported a position in AstraZeneca in Q4 2014 and has held it in 46 quarters since.
- 1,377 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2026.
Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.